Should You Buy Pfizer Stock For Its Cash?

Over the last twelve months, Pfizer (PFE) produced free cash flow equal to 6.5% of its market value, compared with 4.4% for the median S&P 500 company. A yield that high usually points in one of two directions: a business on sale or a business investors expect to shrink. So how solid is the cash behind Pfizer’s yield?

Pfizer’s Cash Has Stayed Positive For Three Years

Pfizer has maintained positive free cash flow in every twelve-month period over the last three years. That metric matters to shareholders even when the cash remains in the company. Investors ultimately own a portion of the free cash a business produces alongside its profit. When the market recognizes that cash generation, the share price tends to follow, especially when the cash grows.

The company generates that cash by selling medicines, nearly all of them through its Biopharma segment. Management said Eliquis, Padcev, the Vyndaqel family and Lorbrena primarily drove the portfolio’s contribution in the second quarter. The company recorded an operating margin of 26.7% over the twelve months to June 2026, up from 26.1% a year earlier. Capital spending consumed only 18% of the cash brought in by operations.

Free cash flow totaled $11.0 billion in those twelve months, down from $12.4 billion a year earlier. However, the business produced $4.81 billion two years earlier. The current cash figure remains well above that low point despite the latest dip.

A portion of that cash must service debt before flowing to equity holders. Pfizer carried a net debt of $51.5 billion, representing borrowings minus cash, at the end of June. That figure amounts to about 30.5% of its market value. When measured against market value plus that debt, the yield is 5.0%. The company generated enough operating profit to cover interest expense 6.3 times over the last twelve months.

Why Investors Doubt Pfizer’s Sales Will Hold

Management provided a forecast pointing to lower sales in 2026. In August, Pfizer guided 2026 revenue to a range of $60.5 billion to $62.5 billion. The midpoint of $61.5 billion sits below the $62.6 billion it reported for 2025, signaling a forecast decline rather than a reported one.

Management named COVID products as the weak spot, cutting its expectation for 2026 COVID revenue to about $4 billion, down from $5 billion. At the same time, revenue excluding COVID products grew 5% operationally in the second quarter. Furthermore, management expects leverage, defined as debt measured against earnings, to stay around its current 2.7 times or move modestly higher over the next few years as some drugs lose exclusivity.

Pfizer has already booked part of the cost of its recent setbacks. In June, a lung cancer trial missed its main goal, and the company recorded $4.3 billion of non-cash impairments in the second quarter. Management is answering with cost cuts and now expects about $9.7 billion in total net savings through 2029. The company also raised its 2026 revenue forecast by $500 million at the midpoint in August, citing strong sales outside COVID.

Based on its reported sales and margins, Pfizer looks more like a business on sale than one in decline. Revenue hit $63.7 billion in the twelve months to June 2026, remaining level with the $63.8 billion recorded in the twelve months prior. The operating margin rose over the same period, though free cash flow fell.

What You Should Watch In Pfizer’s Next Report

Pfizer has yet to show that its cash can keep growing, as free cash flow fell to $11.0 billion over the last twelve months from $12.4 billion the year before. Debt stands as the other open question. Operating profit currently covers interest several times over, but management expects leverage to hold or rise while some drugs lose exclusivity.

Pfizer is expected to release its next report on or around November 3, 2026. Free cash flow over twelve months and leverage will be the two key figures to watch.

Does This Mean You Should Act On PFE?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.